A biotech analyst said the potential sale of Biogen Idec to a major drugmaker could reach up to $30 billion if buyers remain positive on the future of its multiple sclerosis drug Tysabri in the market. However, some stock analysts believe the company might not be able to find a buyer due to competition and Biogen's drug-development deals with Elan Corp. and Genentech.

Related Summaries